Leading Justice is a full-service marketing company working with law firms on a cash-buy basis to sign up fully-qualified, fraud-free Valsartan cancer and liver failure cases. Here at Leading Justice, we can customize your firm’s Valsartan advertising needs and help you sign up cases via internal cash buys. Our clients only pay an agency fee to cover the cost of Valsartan advertising, plus a fee for each case we sign, and any data we generate for you firm belongs to you. We will also cross-qualify all our contacts, meaning any data we generate that doesn’t qualify for the target campaign will be reviewed to determine whether it is eligible for another type of claim. By using advanced approaches to target contacts specifically related to Valsartan and side effects like stomach cancer, pancreatic cancer and liver failure, Leading Justice can increase your firm’s Valsartan case load. If you are interested in helping victims of alleged Valsartan and ARB medication side effects, our direct advertising strategies and extensive consumer reach will give you the confidence and competitive edge you need to allocate your full budget, knowing your money is being used in the best way possible.
Each law firm we work with at Leading Justice plays a key role in determining how we classify claims as qualified or not. And while our experience working with plaintiff law firms helps us recognize a great case when we see one, we will customize our Valsartan and ARB case intake specifications to the exact criteria you are seeking. So, if your firm has specific Valsartan qualifying case criteria you would like us to use, we will train our intake specialists to apply the criteria to each phone call and email they receive. By getting rid of the middle man, Leading Justice offers clients an opportunity for internal cash buys of recalled Valsartan data with no chance of fraud.
Recalled Valsartan Side Effect Litigation
Many popular blood pressure and heart failure medications containing Valsartan have been recalled in the United States and worldwide because of impurities that pose a potential risk of cancer and other serious problems. The FDA issued the first Valsartan recall in July 2018, after the agency found the impurity NDMA (N-nitrosodimethylamine) in drug products containing Valsartan, and several other recalls followed, after other potentially dangerous impurities, like NDEA (N-nitrosodiethylamine) and NMBA (N-Nitroso-N-methyl-4-aminobutyric acid), were discovered in Valsartan products and other similar blood pressure drugs. According to the Environmental Protection Agency, NDMA, NDEA and NMBA all have the potential to cause cancer in humans.
The potentially carcinogenic impurities found in these popular blood pressure medications are believed to have occurred as by-products of the Valsartan manufacturing process at facilities in China and India, and according to reports, can potentially put patients at risk for several different types of cancer and liver damage or liver failure. Additionally, because the chemical reaction that other angiotensin II receptor blockers, like Losartan (Cozarr), Olmesartan (Benicar), Irbesartan (Avapro) and Candesartan (Atacand), undergo during the manufacturing process is similar to the reaction necessary to produce Valsartan, these other medications also have the potential to be contaminated with cancer-causing impurities. In fact, several FDA recalls have been issued for the ARB medications Losartan and Irbesartan recently because of the presence of NDMA, NDEA and/or NMBA, and the drug manufacturers, pharmacies and other companies that made and sold contaminated Valsartan products are now facing a growing number of lawsuits filed by patients who took the recalled drugs.